Zavesca

Land: Australia

Språk: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv ingrediens:

Miglustat

Tilgjengelig fra:

Actelion Pharmaceuticals Australia Pty Limited

Klasse:

Medicine Registered

Informasjon til brukeren

ZAVESCA
®  
MIGLUSTAT 100 MG CAPSULES 

CONSUMER MEDICINE INFORMATION 

WHAT IS IN THIS LEAFLET 

This leaflet answers some 
common questions about 
ZAVESCA. 

It does not contain all the available 
information. 

It does not take the place of talking 
to your doctor or pharmacist. 

All medicines have risks and 
benefits.  Your doctor has weighed 
the risks of you taking ZAVESCA 
against the benefits he/she 
expects it will have for you. 

IF YOU HAVE ANY CONCERNS ABOUT 
TAKING THIS MEDICINE, ASK YOUR 
DOCTOR OR PHARMACIST. 

KEEP THIS LEAFLET WITH THE 
MEDICINE.  You may need to read 
it again. 

THIS LEAFLET CONTAINS INFORMATION 
ON: 
Version: 8 March 2010 
Page 1 of 4 

WHAT ZAVESCA IS USED FOR 
BEFORE YOU TAKE ZAVESCA  
WHEN YOU MUST NOT TAKE IT 
BEFORE YOU START TO TAKE IT 
TAKING OTHER MEDICINES 
HOW TO TAKE ZAVESCA 
HOW MUCH TO TAKE 
HOW TO TAKE IT 
WHEN TO TAKE IT 
HOW LONG TO TAKE IT 
IF YOU FORGET TO TAKE IT 
IF YOU TAKE TOO MUCH 
(OVERDOSE) 
WHILE YOU ARE TAKING ZAVESCA 
THINGS YOU MUST DO 
THINGS YOU MUST NOT DO 
THINGS TO BE CAREFUL OF 
SIDE EFFECTS 
AFTER USING ZAVESCA 
STORAGE 
DISPOSAL 
PRODUCT DESCRIPTION 
WHAT IT LOOKS LIKE  
INGREDIENTS 
MANUFACTURER/SUPPLIER 

WHAT ZAVESCA IS 
USED FOR 

ZAVESCA is a medicine that is 
used to treat mild to moderate 
Type 1 Gaucher disease in 
adults and it is also used to treat 
Niemann-Pick type C disease in 
children, adolescents and 
adults. 

Type 1 Gaucher disease is an 
inherited disease that you get 
from both of your parents.  
People with Type 1 Gaucher 
disease are partially missing an 
enzyme that breaks down a 
chemical in the body called 
glucosylceramide.  Too much 
glucosylceramide causes an 
increase in the size of the liver 
and spleen.  It also causes bone 
disease and changes in the 
blood. 

ZAVESCA reduces the 
formation of glucosylceramide to 
a level the partially missing